Know Cancer

forgot password

Phase II Selective Dose Escalation of Chemoradiotherapy for Esophageal Cancer

Phase 2
18 Years
Open (Enrolling)
Esophageal Cancer

Thank you

Trial Information

Phase II Selective Dose Escalation of Chemoradiotherapy for Esophageal Cancer

we prospectively enrolled patients with T1–4, N0–1, M0–1a esophageal carcinoma to receive
paclitaxel 45 mg/m2 IV over 1 hour and carboplatin AUC 2 IV over 30 minutes on days 1, 8,
15, 22, 29 and 36. 5-FU 225mg/m2 was delivered as a continuous infusion on days 1–38. RT
was given 1.8Gy 5 days/wk for 5.5 wks (50.4Gy in 28 fx). After 6–8 weeks, patients
underwent repeat staging with computed tomography (CT) scan, endoscopic ultrasound (EUS),
and biopsy. Patients with a positive biopsy, or less than PR by CT and EUS, received a
boost of 9 Gy with the same concurrent chemotherapy. Patients were followed every 4 months
with CT/EUS first year, every 6 months thereafter.

Inclusion Criteria:

- T1–4, N0–1, M0–1a esophageal carcinoma

Exclusion Criteria:

- distant metastases

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

survival at 4 years

Principal Investigator

Steven K Seung, MDPhD

Investigator Role:

Study Chair

Investigator Affiliation:

The Oregon Clinic


United States: Institutional Review Board

Study ID:




Start Date:

July 2000

Completion Date:

June 2005

Related Keywords:

  • Esophageal Cancer
  • esophageal cancer, chemotherapy, radiation
  • Esophageal Diseases
  • Esophageal Neoplasms



The Oregon Clinic Portland, Oregon  97213